BioGaia subsidiary IBT takes rapid steps in development of a drug for premature infants

Infant Bacterial Therapeutics (IBT) aims to develop a unique orphan drug to prevent the fatal disease necrotising enterocolitis (NEC). The project has proceeded faster than previously scheduled and according to the updated development plan IBT expects to run two clinical trials within the next three years.

Please see enclosed pdf for full press release.